Clinical Performance Evaluation of the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay

SARS-CoV-2 infections may present with various symptoms that are similar to those of other respiratory diseases. For this reason, the need for simultaneous detection of at least RSV and influenza viruses together with SARS-CoV-2 was evident from the early stages of the pandemic. In the present study, we evaluated the clinical performance of the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay against the conventional low-plex PCR utilized to detect influenza A-B, RSV, and SARS-CoV-2. There were 115 known positive clinical samples and 35 negative controls obtained from asymptomatic health-care workers included in the study; 25 samples were positive for influenza viruses, 46 for RSV, and 44 for SARS-CoV-2. The sensitivity, specificity, positive predictive value, and negative predictive value of the evaluated method for influenza and SARS-CoV-2 were 100%. The Spearman correlation coefficient was 0.586 (p < 0.05) for influenza and 0.893 (p < 0.05) for SARS-CoV-2. The sensitivity of the aforementioned assay for RSV was 93.47%; the specificity and the positive predictive value were 100%, and the negative predictive value was 92.10%, while the Spearman correlation coefficient was not applicable for the RSV. Overall, the assay under evaluation was shown to be a reliable alternative for the simultaneous detection of influenza viruses, RSV and SARS-CoV-2.

[1]  Fann Wu,et al.  Prevalence and Clinical Disease Severity of Respiratory Coinfections During the Coronavirus Disease 2019 Pandemic , 2022, Advances in Molecular Pathology.

[2]  M. Vasse,et al.  Evaluation of Four Fully Integrated Molecular Assays for the Detection of Respiratory Viruses during the Co-Circulation of SARS-CoV-2, Influenza and RSV , 2022, Journal of clinical medicine.

[3]  C. Skevaki,et al.  Respiratory viral co‐infections in patients with COVID‐19 and associated outcomes: A systematic review and meta‐analysis , 2022, Reviews in medical virology.

[4]  F. AlMutawa,et al.  Tracheal Aspirate and Bronchoalveolar Lavage as Potential Specimen Types for COVID-19 Testing Using the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV , 2022, Microbiology spectrum.

[5]  A. Baraniak,et al.  Viral Etiological Agent(s) of Respiratory Tract Infections in Symptomatic Individuals during the Second Wave of COVID-19 Pandemic: A Single Drive-Thru Mobile Collection Site Study , 2022, Pathogens.

[6]  H. Mostafa,et al.  Evaluation of the respiratory NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage and Alinity m Resp-4-Plex assays , 2022, Journal of Clinical Virology.

[7]  Jihad A. M. Alzyoud,et al.  The Prevalence and Impact of Coinfection and Superinfection on the Severity and Outcome of COVID-19 Infection: An Updated Literature Review , 2022, Pathogens.

[8]  J. Wise.  Covid-19: Researchers call for routine flu testing of hospital inpatients with SARS-CoV-2 infection , 2022, BMJ.

[9]  H. Dobrovolny,et al.  Epidemiological Consequences of Viral Interference: A Mathematical Modeling Study of Two Interacting Viruses , 2022, Frontiers in Microbiology.

[10]  J. Baillie,et al.  SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses , 2022, The Lancet.

[11]  A. Papa,et al.  Early initiation of the respiratory syncytial virus season in 2021–2022, Greece , 2022, Journal of medical virology.

[12]  U. Demkow,et al.  The Impact of the COVID-19 Pandemic Lockdown on Pediatric Infections—A Single-Center Retrospective Study , 2022, Microorganisms.

[13]  M. Mandelboim,et al.  Viral co-pathogens in COVID-19 acute respiratory syndrome – what did we learn from the first year of pandemic? , 2021, International Journal of Infectious Diseases.

[14]  S. Metallidis,et al.  Microbiological characteristics of bacteremias among COVID-19 hospitalized patients in a tertiary referral hospital in Northern Greece during the second epidemic wave , 2021, FEMS microbes.

[15]  W. Melchers,et al.  Multi-center evaluation of Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV molecular point-of-care test , 2021, Journal of Clinical Virology Plus.

[16]  Sonia N. Rao,et al.  Syndromic testing for the diagnosis of infectious diseases: the right test if used for the right patient , 2021, The Journal of antimicrobial chemotherapy.

[17]  S. Tsuzuki,et al.  Resurgence of Respiratory Syncytial Virus Infections during COVID-19 Pandemic, Tokyo, Japan , 2021, Emerging infectious diseases.

[18]  L. Brammer,et al.  Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021 , 2021, MMWR. Morbidity and mortality weekly report.

[19]  R. Schooley,et al.  Ten scientific reasons in support of airborne transmission of SARS-CoV-2 , 2021, The Lancet.

[20]  K. Koelle,et al.  The Effect of SARS-CoV-2 Mitigation Strategies on Seasonal Respiratory Viruses: A Tale of Two Large Metropolitan Centers in the United States , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  H. Ghasemzadeh-moghaddam,et al.  High prevalence of SARS‐CoV‐2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran , 2020, Journal of medical virology.

[22]  P. Zhou,et al.  The epidemiology and clinical characteristics of co‐infection of SARS‐CoV‐2 and influenza viruses in patients during COVID‐19 outbreak , 2020, Journal of medical virology.

[23]  P. Hsueh,et al.  Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? , 2020, Journal of Microbiology, Immunology and Infection.

[24]  W. Lim,et al.  Co-infections in people with COVID-19: a systematic review and meta-analysis , 2020, Journal of Infection.

[25]  Xinchun Chen,et al.  Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients , 2020, Science China Life Sciences.

[26]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[27]  Bernstein,et al.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza a , 2018 .

[28]  M. Koopmans,et al.  Challenges in laboratory diagnosis of acute viral central nervous system infections in the era of emerging infectious diseases: the syndromic approach , 2016, Expert review of anti-infective therapy.

[29]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[30]  N. Fishman,et al.  Healthcare Infection Control Practices Advisory Committee , 2012 .

[31]  J. Siegel,et al.  HEALTH CARE INFECTION CONTROL PRACTICES ADVISORY COMMITTEE. 2007 GUIDELINE FOR ISOLATION PRECAUTIONS: PREVENTING TRANSMISSION OF INFECTIOUS AGENTS IN HEALTH CARE SETTINGS , 2007 .

[32]  M. Jackson,et al.  Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007. , 2007 .

[33]  I. Casas,et al.  Simultaneous detection of influenza A, B, and C viruses, respiratory syncytial virus, and adenoviruses in clinical samples by multiplex reverse transcription nested‐PCR assay , 2003, Journal of medical virology.

[34]  C B Hall,et al.  Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. , 1998, The Journal of general virology.